Detroit Clinical Research Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2013
NCT02038218
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Detroit Clinical Research Center | Detroit Clinical Research Center, Farmington Hills, Lansing and Owasso, MI

Active Ingredients

Drugs in Phase 2 Trials (1)

4-demethyl-4-cholesteryloxycarbonylpenclomedine (2 trials)

Drugs in Other Trials (1)

rimabotulinumtoxinB (Myobloc) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2